Neisseria Meningitidis Outer Membrane Vesicles

drug
On this page

Summary

Neisseria Meningitidis Outer Membrane Vesicles (CHEMBL6068370) is an approved vaccine component; indicated across 2 conditions including meningococcal meningitis.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Vaccine component
  • Indications: 2 conditions

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL6068370
NameNeisseria Meningitidis Outer Membrane Vesicles
TypeVaccine component
Max phase4

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

IndicationPhaseMONDOEFO
meningococcal meningitis4MONDO:0018059EFO:1001040

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).